The case for & against
Bull & Bear analysis
Treace Medical Concepts, Inc. (NASDAQ: TMCI) specializes in innovative surgical solutions primarily focused on bunion correction technologies. With a significant transition from its foundational lapoplasty offerings to a broader suite of bunion solutions, the company aims to capture a larger share of the estimated 1.1 million annual bunion surgeries in the U.S., positioning itself strategically within the orthopedic surgical solutions market, valued at approximately $5 billion. Its recent product innovations, including the new HyperPlate™ XM Dynamic Compression Locking Implant System, serve to enhance its market presence amidst a competitive landscape within the medical-device sector.
Bull says
- ↑Launched three new bunion systems, expecting volume growth in 2025
- ↑Active surgeon base achieved ~35% adoption of new systems
- ↑Cash usage cut by ~50% Y/Y; cash reserves $51.9 M
- ↑Adjusted EBITDA loss narrowing, reflecting improved cost control
- ↑Seasonal Q4 demand likely to drive meaningful revenue uplift
- ↑Strong balance sheet quality supports ongoing innovation
Bear says
- ↓Q1 revenue fell 10% to $47.2 M; full-year guide set at −5% to flat
- ↓Net loss grew to $18 M ($0.28/sh), underscoring weak profitability
- ↓Full-year adjusted EBITDA loss expected, signaling ongoing cash burn
- ↓Shift toward lower-priced products may curb surgeon procedure volumes
- ↓Intense competition from larger orthopedic players pressures pricing
- ↓Poor profitability and growth factor metrics point to continued headwinds
Investment themes with TMCI
Clinical instruments and devices powering patient care
Earnings Call · Q1 2026 · Mgmt. Guidance
Transcript signals
Bull points
- We believe these three new systems more than double our accessible market relative to lapoplasty alone, making their successful commercialization and deeper market penetration an important priority as we look to drive incremental growth.
- We believe this position is well to expand adoption and drive greater penetration over time across the estimated 4.4 million annual US bunion sufferers.
- Market penetration with these three products is increasing. While just three quarters into our full launch, we continue to see a strong uptake of our new systems and a corresponding acceleration in our procedure volumes, resulting in market share gains.
Bear points
- We reported revenue declines of approximately 10% in Q1, and we believe this trend will improve over time as we annualize the launch of the new products we launched in 2025.
- We anticipate to continue to see that until we begin to lap or to have an anniversary of when we made these new products available. It's really in the third quarter of this year. So some of these dynamics we fully anticipate to continue. This is the exact dynamics that we talked about.
- we have not given any formal guidance with respect to 2027, but I can tell you that we are expecting to return to revenue growth in the fourth quarter this year. So I think it's going to be a little bit early to talk about 2027.